HEALTH

Inverness makes the move to China

BY Michael Johnsen

WALTHAM, Mass. Inverness Medical Innovations will be transferring production of its consumer diagnostics to Chinese facilities from its facility in England, the company announced Thursday.

The company intends to close its Unipath facility based in Bedford, England. During the second half of 2007, Unipath manufactured approximately 53 million tests, of which approximately 46 million were supplied to Inverness’ 50/50 consumer diagnostics joint venture. Inverness anticipates that the closure and transfer could be completed by year-end 2009.

The intention to move represents an acceleration of Inverness’ ongoing plans to significantly reduce product cost, increase margins and extend product life cycles for its women’s health and professional diagnostic product lines.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

eDiets announces alli-partnered meal delivery available

BY Michael Johnsen

FORT LAUDERDALE, Fla. eDiets.com on Wednesday announced the immediate availability of its fresh meal delivery program specially designed to coordinate with GlaxoSmithKline’s alli product for weight loss.

“eDiets does all of the calorie counting, thinking and planning for the alli program, so users don’t need to,” stated Pamela Ofstein, director of nutrition services for eDiets.

eDiets fresh meal delivery plans are available in 5 or 7 day plans for $15.95 a day plus shipping.

The launch follows last week’s announcement of the relationship with GlaxoSmithKline Consumer Healthcare, the company stated

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

NanoMask final test shows better than 99 percent effectiveness

BY Michael Johnsen

LAS VEGAS Emergency Filtration Products on Wednesday announced the results of the final report for the assessment of virucidal effectiveness of treated masks (the NanoMask filter media) using avian influenza virus from the independent testing laboratory which conducted the test.

According to the final report, the test resulted in a 99.96 percent reduction of the avian influenza virus.

The final report was based on filter media samples coated with a silver nanoparticle formulation which underwent one year of simulated aging. The sample was challenged with the avian influenza strain H9N2.

This result compares favorably with a previously disclosed result which indicated a 99.75 percent reduction obtained from a preliminary report by the same independent testing laboratory.

EFP plans to complete a series of tests necessary to the information required to support its 510(k) submission to the FDA for the NanoMask, the company announced in November, including tests of accelerated aging, with follow-on efficacy testing, which ascertains the product’s ability to kill pathogens after a prolonged period of time. This will help determine the NanoMask’s accurate shelf life for inventory purposes.

Other testing expected to be completed prior to completion of the accelerated aging test are leaching tests, which ensure that the silver nanoparticle formulation does not separate from the filter media.

Sales of the NanoMask have been held pending FDA approval, at least according to the handful of web sites advertising the NanoMask. The mask, however, appears to have been designed for the consumer market—there are presently five adult masks (yellow, green, red, blue and purple) and three child masks (yellow, green and purple), all advertised for $12.99 on birdfluprotection.com. Similarly, a 10-pack of replacement filters also retails for $12.99 on the site. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?